1,10-Decanediol | CAS:112-47-0

We serve 1,10-Decanediol CAS:112-47-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1,10-Decanediol

Chemical Name:  1,10-Decanediol
CAS.NO:112-47-0
Synonyms:decane-1,10-diol
1,10-Ddecanediol
1,10-Dihydroxydecane
1,10-Decanediol
Decamethylene glycol
 
Molecular Formula:C10H22O2
Molecular Weight:174.28000
 
Physical and Chemical Properties:
Density:1,08 g/cm3
Boiling point:297 °C
Melting point:70-73 °C
Flash point:152 °C
Index of Refraction:1.457
 
Specification:
Appearance:White crystal
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 1. For the preparation of flavors and fragrances
2. Pharmaceutical intermediates.
3,1,10-Decanediol (112-47-0) is used to produce diiododecane to prepare antibacterial and antimycotic drugs (di) clopidine and otinidine, etc., and to prepare adhesive , Special materials, etc.



Contact us for information like 1,10-Decanediol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Decamethylene glycol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,10-Decanediol Use and application,1,10-Decanediol technical grade,usp/ep/jp grade.


Related News: For example, an active ingredient to relieve pain is included in a painkiller.4-methylsalicylic acid manufacturer For example, an active ingredient to relieve pain is included in a painkiller.(R)-2,3-Dihydro-1H-Inden-1-Amine Hydrochloride supplier f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national.4-Bromoisoquinoline vendor With the onset of the DMF system for APIs, the concentration of the API industry will further increase.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.